Aspartate transaminase to platelet ratio index in hepatitis C virus and *Schistosomiasis* coinfection

Moutaz Derbala, Mohammed Elshiekh Elbadri, Aliaa Mohamed Amer, Saad AlKaabi, Khaleel Hassan Sultan, Yasser Medhat Kamel, Eman Hassan Satti Elsayed, Tony Yervant Avades, Prem Chandra, Fatma M Shebl

Informed consent statement: Waiver form according to the Research committee roles for retrospective study.

Conflict-of-interest statement: The authors declare that they have no conflict of interest.

Open-Access: This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

Correspondence to: Moutaz Derbala, Consultant, Gastroenterology and Hepatology, Hamad General Hospital, Doha 00974, Qatar. mod2002@qatar-med.cornell.edu

Telephone: +974-4-4392532
Fax: +974-4-4392532

Received: June 30, 2015
Peer-review started: July 4, 2015
First decision: July 19, 2015
Revised: August 4, 2015
Accepted: September 14, 2015
Article in press: September 15, 2015
Published online: December 14, 2015

**Abstract**

**AIM:** To assess the diagnostic accuracy, of amino-transferase-to-platelet ratio index (APRI) alone and with antischistosomal antibody (Ab) in patients with hepatitis C virus (HCV) and schistosomiasis coinfection.

**METHODS:** This retrospective study included medical records of three hundred and eighty three Egyptian
men patients who had undergone percutaneous liver biopsy between January 2006 to April 2014 in tertiary care hospital in Qatar for diagnosis or monitoring purpose were selected. Data of patients > 18 years of age were included in the study. The values of HCV RNA titer and antischistosomal antibody titer were also taken into consideration. Patients were excluded from the study if they had any other concomitant chronic liver disease, including; history of previous antiviral or interferon therapy, immunosuppressive, therapy, chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, prior liver transplantation, and if no data about the liver biopsy present.

RESULTS: Median age of patients was 46 years. About 7.1% had no fibrosis, whereas 30.4%, 37.5%, 20.4%, and 4.6% had fibrosis of stage I, II, III, and IV respectively. In bivariate analysis, APRI score, levels of AST, platelet count and age of patient showed statistically significant association with liver fibrosis (P < 0.0001); whereas antischistosomal antibody titer (P = 0.52) and HCV RNA titer (P = 0.79) failed to show a significant association. The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% respectively. This showed good sensitivity and specificity of APRI alone for grading of liver fibrosis. But the inclusion of anti-Schistosoma antibody did not improve the prediction of fibrosis stage.

CONCLUSION: The study results suggest that noninvasive biochemical markers like APRI are sensitive and specific in diagnosing the degree of fibrosis and cirrhosis in patients with coinfection of HCV and schistosomiasis as compared to biopsy. The addition of antischistosomal Ab to APRI did not improve sensitivity for predicting the degree of cirrhosis.

Key words: Hepatitis C; Schistosomiasis; Aspartate transaminase to platelet ratio index; Liver biopsy; Liver fibrosis

© The Author(s) 2015. Published by Baishideng Publishing Group Inc. All rights reserved.

Core tip: In few parts of the world, in addition to hepatitis C virus (HCV) other concomitant infections play a significant role in causing liver fibrosis. This study was conducted using data from 383 patients to evaluate accuracy of noninvasive method called aspartate transaminase to platelet ratio index (APRI). Its usefulness was explored for assessment of liver fibrosis. Also the role of anti-schistosomal antibody was evaluated for improving sensitivity and specificity of APRI. The APRI when used alone showed good sensitivity and specificity for accurately evaluating liver fibrosis in patients with HCV and schistosomiasis coinfection. The addition of antischistosomal antibody or HCV-RNA Titer, did not further improve the accuracy of APRI.
who are also co-infected with schistosoma infection.

Significant research gaps continue to limit full understanding of the benefits and harms of screening for HCV infection and diagnostic accuracy of non-invasive tests to compare to the liver biopsy. Although liver biopsy is still regarded as the most accurate method for assessing the histological stage of HCV infection and its complications in liver; it is an invasive test with some risks for serious harms, making work-up strategies that make use of noninvasive tests with high diagnostic accuracy a potential alternative.

The relationship between platelet count and the stages of fibrosis in chronic HCV hepatitis have been examined previously, however few reports have studied this association in patients infected with Schistosoma mansoni[8]. The question, whether schistosomiasis-HCV coinfection can affect the sensitivity of APRI score in this group of patients needs attention. Also, it is important to know does antischistosomal Ab titer can modify the sensitivity of APRI score in these patients.

As per World Health Organization, in resource-limited countries, it is recommended to use noninvasive tests for the assessment of hepatic fibrosis rather than other invasive and methods requiring more resources[10].

This retrospective study was conducted to examine the diagnostic accuracy of one such noninvasive test for resource poor countries like Egypt; the APRI, in adult patients with combined schistosoma and HCV infection compared to non-shistosoma infected patients. We also tried assessing the value of adding antischistosomal Ab titer to the APRI score on its sensitivity and specificity for fibrosis staging.

**MATERIALS AND METHODS**

The data analyzed in the study were obtained after approval from the ethics committee for human research of the Hamad Medical Corporation. The study was conducted in accordance with the Declaration of Helsinki. This study was done in the Department of Hepatology at Hamad General Hospital. A retrospective analysis of medical records of 383 men patients with HCV infection who had undergone percutaneous liver biopsy between January 2006 to April 2014 was done. Those patients were scheduled to receive treatment for HCV infection. Chronic HCV infection was defined as positive anti-HCV serology, active virus replication was manifested by the detection of HCV-RNA, a persistent increase in alanine aminotransferase (ALT), and chronic active hepatitis histological pattern. Patients 18 years or older, with confirmed diagnosis of HCV infection were included in the study. Patients were excluded from the study if they had any other concomitant chronic liver disease, including chronic hepatitis B infection, human immunodeficiency virus co-infection, autoimmune hepatitis, decompensated liver disease, hepatocellular carcinoma, history of previous antiviral or interferon therapy, immunosuppressive therapy, prior liver transplantation, and if no data about the liver biopsy present. Diagnosis of schistosomal co-infection was based on positive antischistosomal antibody titer equal to or more than 1:160 (Fumouze Diagnostics, Levallois-Perret, France).

HCV-RNA detection was done using the QIAamp Viral RNA and RNeasy Mini kit (QIAGEN, Hilden, Germany) according to manufacturer’s instructions. Scheuer score was used for assessing necro-inflammatory activity and fibrosis in liver biopsies of patients with chronic viral hepatitis. APRI Score was calculated at the same time with liver biopsy.

**Statistical methods**

All analyses were run using SAS 9.4. Data were presented as median with interquartile range, and frequencies with percentages. The bivariate analysis was done using χ² test/Fisher exact test for categorical variables and Kruskal-Wallis test for continuous variables to find out the association between other factors/variables and fibrosis. Binary and multinomial logistic regressions were used to examine the predictors of fibrosis modeled as dichotomous or multi-categories fibrosis status respectively. All models were forced to retain the APRI score as predictors. P < 0.05 indicated that the associations were statistically significant. The receiver characteristic curve (ROC) analysis was used to analyze the accuracy of diagnosis of the hepatic fibrosis. An area under the ROC curve value close to one, indicated high diagnostic accuracy. Because sensitivity and specificity were considered equally important, the best cutoff points were determined using Youden’s index which maximizes sensitivity and specificity. To examine the possible role of anti-schistosomiasis in improving prediction of fibrosis stage, we compared AUC of three models predicting each fibrosis stage; namely model 1 which included APRI as the only predictor of fibrosis stage, model 2 which included anti-schistosomiasis as the only predictor of fibrosis stage, and model 3 which included both APRI and anti-schistosomiasis as predictors of fibrosis stage. The volume under the surface (VUS) method was used additionally as an extension to AUC, using a three-class fibrosis variable model[11]. A VUS less than or equal to 16.7% is considered worthless in prediction of fibrosis. To calculate the VUS we used a non-parametric method that uses a confusion matrix approach[12]. Analysis of VUS was conducted using the SAS macro written by Kapasny and Rezac[13].

Fibrosis status were classified in several ways; two-class variables (1) any fibrosis yes (stage 1 to 4) vs no (stage 0); (2) significant fibrosis (stage 2, 3, 4) vs no/low fibrosis (stage 0, 1); (3) severe fibrosis (stage 3, 4) vs no/low/mild fibrosis (stage 0, 1, 2); and (4) cirrhosis (stage 4) vs no/low/mild/moderate fibrosis (stage 0, 1, 2, 3). A three-class fibrosis status was

---

Derbala M et al. APRI in concomitant HCV-Schistosomiasis confection

From WJG Online December 14, 2015 Volume 21 Issue 46

WJG | www.wjgnet.com 13134
Table 1  Population characteristics and bivariate association with fibrosis

| Characteristic          | Median (inter-quartile range) | Bivariate analysis$^1$ (P value) |
|-------------------------|------------------------------|---------------------------------|
| Age                     | 46 (38, 52)                  | < 0.0001                        |
| APRI score              | 0.63 (0.40, 1.11)            | < 0.0001                        |
| Anti-schistosoma antibody| 128 (0, 512)                | 0.53                            |
| HCV RNA titer (Log10)   | 5.60 (4.98, 6.17)            | 0.38                            |
| AST                     | 42 (31, 63)                  | < 0.0001                        |
| Platelet ($\times 10^3$) | 192 (147, 232)              | < 0.0001                        |
| Fibrosis, n (%)         | NA                           | NA                              |
| No                      | 26 (7.1)                     | -                               |
| Stage I                 | 112 (30.4)                   | -                               |
| Stage II                | 138 (37.5)                   | -                               |
| Stage III               | 75 (20.4)                    | -                               |
| Stage IV                | 17 (4.6)                     | -                               |
| Grade, n (%)            | NA                           | < 0.0001$^1$                    |
| 0                       | 2 (0.54)                     | -                               |
| I                       | 101 (27.4)                   | -                               |
| II                      | 185 (50.1)                   | -                               |
| III                     | 74 (20.1)                    | -                               |
| IV                      | 7 (1.90)                     | -                               |

$^1$Kruskal-Wallis test; $^2$Fisher exact test. $P < 0.05$ is considered significant. NA: Not applicable.

defined as no (stage 0), mild/moderate (stage 1, 2), severe/cirrhosis (stage 3, 4).

RESULTS

The study included 383 men patients. The participants were all men. Median age was 46 (38-52). Approximately 26 (7.1%) had no fibrosis, whereas 112 (30.4%), 138 (37.5%), 75 (20.4%), and 17 (4.6%) had fibrosis of stage I, II, III, and IV respectively.

In bivariate analysis, APRI score, levels of AST, platelets count and age of patient showed statistically significant association with liver fibrosis ($P < 0.0001$). Antischistosoma antibody titer ($P = 0.53$) and HCV RNA titer ($P = 0.38$) did not show a significant association with liver fibrosis. More specifically, there were significant difference in levels of APRI scores among the groups of no fibrosis, stage 1, 2, 3 and 4 fibrosis; median (IQR) 0.42 (0.34, 0.71), 0.44 (0.35, 0.63), 0.64 (0.41, 0.92), 1.22 (0.62, 2.22), and 2.49 (1.40, 2.80) respectively (Kruskal-Wallis test: $\chi^2 = 98.78, P < 0.0001$). The result is summarized in Table 1.

In the multivariable logistic regression analysis, we further explored predictors of fibrosis status. APRI score did not significantly predict "no fibrosis" status, while age significantly predicted "no fibrosis" status, such that for a unit increase in the APRI score the odds of "no fibrosis" decreased by 16%, while for each 5-year increase in age, there was approximately 35% decrease in the odds of "no fibrosis"; OR (95%CI) 0.84 (0.45-1.57) and 0.65 (0.51-0.83) respectively. On examining predictors of "significant fibrosis" status, APRI score, older age, and severe inflammation significantly predicted "significant fibrosis" status; OR (95%CI) 2.48 (1.45-4.25), 1.23 (1.05-1.44), and 13.03 (6.90-24.60) respectively. Similarly APRI score, older age, and severe inflammation grade significantly predicted "severe fibrosis" status OR (95%CI) 3.53 (2.37-5.24), 1.29 (1.08-1.54) and 9.18 (2.44-34.60) respectively. Interestingly, for each unit increase in APRI score there was a 68% increase in the odds of "cirrhosis" status OR (95%CI) 1.68 (1.08-2.61), and for each 10000 unit increase in platelet count, there was a 15% decline in the odds of "cirrhosis" status OR (95%CI), 0.85 (0.73-0.98) (Data are not in tables).

We also ran the multinomial logistic regression model to predict a three-level, fibrosis status (no, mild/moderate, severe/cirrhosis). Compared to no fibrosis, the probability of mild/moderate fibrosis was not significantly predicted by APRI score or grade, but significantly predicted by age. On the contrary, the probability of severe fibrosis/cirrhosis was significantly higher for individuals with higher APRI score, who are older and have moderate/severe inflammation (Table 2).

To examine the improvement in predicting fibrosis when anti-schistosoma antibodies is included as predictor of fibrosis, we ran three models. The first model included APRI score only, the second model included anti-schistosoma antibodies only, and the third model included both APRI score and anti-schistosoma antibodies.

The respective AUC values for no fibrosis, significant fibrosis, severe fibrosis and cirrhosis of APRI score were 63%, 73.2%, 81.1% and 88.9% (Figure 1). The individual APRI has shown good sensitivity and specificity as compared to biopsy. The sensitivity and specificity increase as grades of fibrosis increases. Because sensitivity and specificity were considered equally important, the best cutoff points were determined using Youden’s index which maximizes sensitivity and specificity. APRI score did not perform well in predicting no fibrosis. The optimal cutoff point was 0.45. The cutoff for significant fibrosis, severe fibrosis and cirrhosis was 0.64, 1.06 and 1.11 respectively. The results are summarized in Table 3.

We investigated whether the prediction of fibrosis stage would improve if both antischistosoma antibody and APRI score were included in the prediction model.

Table 2  Odds ratio estimates and Wald confidence intervals of multinomial regression predicting fibrosis status

| Predictor          | Outcome/fibrosis | Unit | OR       | 95%CI    | P value |
|--------------------|------------------|------|----------|----------|---------|
| APRI SCORE         | Severe/cirrhosis | 1    | 2.41     | 1.12-5.18| 0.025   |
| APRI SCORE         | Mild/moderate    | 1    | 0.65     | 0.31-1.40| 0.275   |
| AGE                | Severe/cirrhosis | 5    | 1.83     | 1.37-2.46| < 0.0001|
| AGE                | Mild/moderate    | 5    | 1.46     | 1.14-1.88| 0.003   |
| Grade              | Severe/cirrhosis | NA   | 11.63    | 2.41-56.12| 0.002   |
| Stage              | Mild/moderate    | NA   | 1.29     | 0.51-3.28| 0.587   |

NA: Not applicable.
But inclusion of anti-schistosoma antibody did not improve the prediction of fibrosis stage (Table 4).

Using a three class fibrosis variable (no fibrosis, mild to moderate fibrosis and severe cirrhosis) a VUS of 43% was observed. We investigated cutoff points that minimize misclassification. Cut off points of (no fibrosis < 0.2, mild/moderate fibrosis 0.2 to < 0.7, and severe/cirrhosis > 0.7) achieved a 62.5% correctness. The correct classification was achieved in approximately 73.1% if we used cutoffs of (no fibrosis < 0.2, mild/moderate fibrosis 0.2 to < 1.0, and severe/cirrhosis > 1.0). Approximately 76.1% subjects were correctly classified using the cutoff points of (no fibrosis < 0.2, mild/moderate fibrosis 0.2 to < 1.5, and severe/cirrhosis > 1.5). Increasing the cutoff point of severe/cirrhosis to APRI score of 2 decreased the correctness of classification to 74.5% (no fibrosis < 0.2, mild/moderate fibrosis 0.2 to < 0.7, and severe/cirrhosis > 1.0).

### Table 3

Aminotransferase-to-platelet ratio index score AUC, cutoff points and accuracy in determining fibrosis

| Characteristic | AUC  | Cutoff point | Sensitivity | Specificity |
|----------------|------|--------------|-------------|-------------|
| No fibrosis    | 63%  | 0.45         | 56%         | 69%         |
| Significant fibrosis | 73%  | 0.64         | 63%         | 76%         |
| Severe fibrosis | 81%  | 1.06         | 64%         | 86%         |
| Cirrhosis      | 89%  | 1.11         | 88%         | 79%         |

1Based on Youden's index.

### Table 4

Comparison of AUC of models that include aminotransferase-to-platelet ratio index score only, anti-schistosomiasis only or aminotransferase-to-platelet ratio index score plus anti-schistosomiasis in determining fibrosis

| Characteristic | Model 1 | Model 2 | Model 3 |
|----------------|---------|---------|---------|
| No fibrosis    | 63%     | 54%     | 60%     |
| Significant fibrosis | 73% | 55%     | 73%     |
| Severe fibrosis | 81%     | 54%     | 81%     |
| Cirrhosis      | 89%     | 52%     | 89%     |

1Model includes APRI score; 2Model includes anti-schistosomiasis; 3Model includes APRI score plus anti-schistosomiasis. APRI: Aminotransferase-to-platelet ratio index.

Figure 1 Receiver characteristic curve analysis of aminotransferase-to-platelet ratio index. Score in predicting grades of fibrosis.
mild/moderate fibrosis 0.2 to < 2, and severe/cirrhosis > 2). In general, the highest misclassification was in the no fibrosis class, while the lowest misclassification was in the mild/moderate fibrosis class (Figure 2).

**DISCUSSION**

In this study, we explore for the first time the utility of anti-schistosoma antibodies in improving the diagnostic accuracy of APRI score. World Health Organization estimates that of the world's population, about 3% has been infected with HCV and that there are approximately more than 170 million chronic carriers who are at risk of developing liver cirrhosis and liver cancer. Egypt has one of the highest prevalence of HCV and a high morbidity and mortality from chronic liver disease, cirrhosis, and hepatocellular carcinoma. About 20% of blood donors in Egypt are anti-HCV positive. Compared to other countries in the world which share similar socioeconomic conditions and equivalent sterilization, infection control and hygienic standards for invasive medical, dental, or paramedical procedures, Egypt has considerable higher rates of HCV.

In Egypt, the major route of exposure is considered to be due to receiving medical injections and inefficient infection control practices. Also, due to blood and blood products transfusions prior to 1994. Of note, the reported major risk factor is a history of antischistosomal injection treatment prior to 1986. Historically, Schistosomiasis used to be a common parasitic disease in Egypt which were commonly acquired through engaging in activities such as swimming or wading in Schistosoma-contaminated irrigation channels or standing water. Because, during the 90s, only glass syringes were available for treatment of schistosomiasis, which were usually inadequately sterilized by boiling, lead to an iatrogenic HCV epidemic in Egypt. Overall, despite improvement in schistosomiasis-related morbidity during 90s, such treatment campaigns set the stage for the current large hepatitis disease burden in Egypt.

Considering all epidemiological significance, in this study, we tried to find out if a noninvasive method called APRI is sensitive enough to predict degree of fibrosis as accurately as liver biopsy. Also we tried to find out if addition of antischistosomal Ab titer in APRI increases the diagnostic accuracy of procedure.

In this study, we found that the degrees of liver fibrosis of patients with chronic hepatitis C were strongly associated with APRI score, levels of AST, platelets count and age of patient. There was no statistically significant association with antischistosoma antibody titer and HCV RNA titer. Various other studies tried to find out multiple factors related to liver fibrosis progression in HCV infection. Inconsistent reports were found regarding association of biomarkers. In study by Ryder et al., age was found to have significant association, but no association was found with AST levels. Whereas, in a study by Butt et al., there were positive associations between HCV RNA and duration of HCV infection with fibrosis.

The APRI is calculated as (AST/upper limit of normal range)/platelet count (10^9/L) \times 100. The accuracy of APRI was improved with higher grade of fibrosis. It was estimated using ROC curves. This finding was similar as reported by many other studies. But few studies concluded that APRI may not be sensitive enough to be used as a routine practice. The results may have been because of smaller sample size used in such studies. APRI index has been validated as a
surrogate marker of significant hepatic fibrosis in HIV/HCV-coinfected patients, and has recently been used to determine advanced fibrosis in HIV-monoinfected patients. And recently metaanalysis also supported its use for assessment of liver fibrosis in patients of chronic HCV infection[22].

Addition of antischistosomal antibody to APRI was also evaluated. This addition did not improve the predictive capacity of APRI. That also did not decrease the predictive capacity of APRI suggesting that it is an independent marker and is not responsible for or may be involved with very insignificant fibrosis. There are no other published studies using antischistosomal antibody with APRI for diagnosis of liver fibrosis in chronic HCV infection.

We also tried additional method for examining three-class indicators of fibrosis status. It was an extension of the ROC analysis method, known as VUS. Using this method we found that the highest misclassification was in the no fibrosis class, while the lowest misclassification was in the mild to moderate fibrosis class.

One of the main reasons for doing this study was because of many contradicting reports about HCV-schistosoma coinfection and its impact. As per many studies, the HCV-schistosoma coinfection is a very important disease in Egyptian patients. It is reported that, the prevalence of schistosomal co-infection among HCV-Egyptian patients is up to 27.3%. And this figure may increase as per the histological activity index. It is suggested that this correlation may interfere with liver fibrosis assessment of Egyptian patients[23-25]. While other studies have denied any impact of schistosomal co-infection on the outcome of HCV infection, in regard of liver pathology or HCV-specific cell-mediated immunity[26].

Of note, we included only men because of the very small number of women who have been seen in our clinic. Therefore, our results might not be generalizable to women.

A validated noninvasive marker of fibrosis is useful in patients with liver fibrosis. Such a marker could help guide clinicians in whom to treat, and serve as a longitudinal marker of treatment efficacy without the need for repeated liver biopsies. Even WHO recommends using such methods in resource poor countries for monitoring. The results of this study indicate that APRI is a useful marker in patients with coinfection of HCV and schistosomiasis. Our next study is intended to try to find a more sensitive model for schistosomal patients with HCV coinfection, using other simple noninvasive parameters to improve the sensitivity of APRI score. Further research is needed in this area to verify APRI or identify other noninvasive markers that are reliable and feasible for use in patients with HCV and other coinfection like schistosoma.

**REFERENCES**

1. Elesawy BH, Abd El Hafez A, Dorgham LS, El-Askary A. Limited reliability of five non-invasive biomarkers in predicting hepatic fibrosis in chronic HCV mono-infected patients opposed to METAVIR scoring. Pathol Res Pract 2014; 210: 922-928 [PMID: 25123964 DOI: 10.1016/j.prp.2014.07.005]
2. Sebastiani G, Glouvatos K, Pantopoulos K. Chronic hepatitis C and liver fibrosis. World J Gastroenterol 2014; 20: 11033-11053 [PMID: 25170193 DOI: 10.3748/wjg.v20.i32.11033]
3. Trifan A, Stanciu C. Checkmate to liver biopsy in chronic hepatitis C? World J Gastroenterol 2012; 18: 5514-5520 [PMID: 23112543 DOI: 10.3748/wjg.v18.i39.5514]
4. Liu T, Wang X, Karsdal MA, Leeming DJ, Genovesi F. Molecular serum markers of liver fibrosis. Biomark Insights 2012; 7: 105-117 [PMID: 22872786 DOI: 10.4137/BMI.S10009]
5. El-mezyanen HA, Toson el-SA, Shiba GE. Role of hyaluronic acid, its degrading enzymes, degradation products, and ferritin in the assessment of fibrosis stage in Egyptian patients with chronic hepatitis C. Eur J Gastroenterol Hepatol 2013; 25: 69-76 [PMID: 23011038 DOI: 10.1097/EJG.0b013e3283594924]
6. Attallah AM, Abdallah SA, Attallah AA, Omran MM, Farid K, Nasif WA, Shiba GE, Abdel Aziz AA, Rasafy N, Shaker YM. Diagnostic value of fibronectin discriminant score for predicting liver fibrosis stages in chronic hepatitis C virus patients. Ann Hepatol 2013; 12: 44-53 [PMID: 23293193]
7. Borsoi Viana MS, Taki E, Collarile Yamaguti DC, Guz B, Strauss E. Use of AST platelet ratio index (APRI Score) as an alternative to liver biopsy for treatment indication in chronic hepatitis C. Ann Hepatol 2009; 8: 26-31 [PMID: 19221530]
8. Dai CY, Ho CK, Huang JP, Hsieh MY, Hou NJ, Lin ZY, Chen SC, Hsieh MY, Wang LY, Chang WY, Yu ML, Chuang WL. Hepatitis C virus viremia and low platelet count: a study in a hepatitis B &
C endemic area in Taiwan. J Hepatol 2010; 52: 160-166 [PMID: 20034694 DOI: 10.1016/j.jhep.2009.11.017]

9 Medeiros TB, Domingues AL, Luna CF, Lopes EP. Correlation between platelet count and both liver fibrosis and spleen diameter in patients with schistosomiasis mansoni. Arq Gastroenterol 2014; 51: 34-38 [PMID: 24760062]

10 World Health Organization. Hepatitis C: Fact Sheet. Available from: URL: http://www.who.int/mediacentre/factsheets/fs164/en/

11 Mossman D. Three-way ROCs. Med Decis Making 1999; 19: 78-89 [PMID: 9917023]

12 Kang L, Tian LL. Estimation of the volume under the ROC surface with three ordinal diagnostic categories. Comput Stat Data An 2013; 62: 39-51

13 Juraj K, Martin R. Three-way ROC analysis using SAS Soft ware. Acta Universitatis Agriculturae et Silviculturae Mendelianae Brunensis 2013; LXI: 2269-2275 [DOI: 10.11118/actaun201361072269]

14 World Health Organization. Hepatitis C: Global response and alert. Available from: URL: http://www.who.int/csr/disease/hepatitis/whocdscsrlyo2003/en/index4.html

15 Mohamoud YA, Muntaz GR, Risone S, Miller D, Abu-Raddad LJ. The epidemiology of hepatitis C virus in Egypt: a systematic review and data synthesis. BMC Infect Dis 2013; 13: 288 [PMID: 23799878 DOI: 10.1186/1471-2334-13-288]

16 Ryder SD, Irving WL, Jones DA, Neal KR, Underwood JC. Progression of hepatic fibrosis in patients with hepatitis C: a prospective repeat liver biopsy study. Gut 2004; 53: 451-455 [PMID: 14960533]

17 Butt AA, Yan P, Lo Re V, Rimland D, Goetz MB, Leaf D, Freeberg MS, Klein MB, Justice AC, Sherman KE. Liver fibrosis progression in hepatitis C virus infection after seroconversion. JAMA Intern Med 2015; 175: 178-185 [PMID: 25485735 DOI: 10.1001/jamainternmed.2014.6502]

18 Li SM, Li GX, Fu DM, Wang Y, Dang LQ. Liver fibrosis evaluation by ARFI and APRI in chronic hepatitis C. World J Gastroenterol 2014; 20: 9528-9533 [PMID: 25071348 DOI: 10.3748/wjg.v20.i28.9528]

19 Amorim TG, Staub GJ, Lazzarotto C, Silva AP, Manes J, Ferro-nato Mda G, Shiozawa MB, Narciso-Schianov JL, Dantas-Correia EB, Schianov Lde L. Validation and comparison of simple noninvasive models for the prediction of liver fibrosis in chronic hepatitis C. Ann Hepatol 2012; 11: 855-861 [PMID: 23109448]

20 Khan DA, Fatima-Tuz-Zuhra FA, Mubarak A. Evaluation of diagnostic accuracy of APRI for prediction of fibrosis in hepatitis C patients. J Ayub Med Coll Abbottabad 2008; 20: 122-126 [PMID: 19999223]

21 Karoui S, Ben Romdhane S, Serghini M, Ben Mustapha N, Boubaker J, Haouet S, Filali A. [Is APRI score a suitable tool for prediction of fibrosis in Tunisian patients with genotype 1 chronic viral hepatitis C?]. Tunis Med 2012; 90: 282-285 [PMID: 22535341]

22 Baranova A, Lal P, Birerdinc A, Younossi ZM. Non-invasive markers for hepatic fibrosis. BMC Gastroenterol 2011; 11: 91 [PMID: 21849046 DOI: 10.1186/1471-230X-11-91]

23 Abdel-Rahman M, El-Sayed M, El Raziky M, Elsharkawy A, El-Akel W, Ghoneim H, Khattab H, Esmat G. Coinfection with hepatitis C virus and schistosomiasis: fibrosis and treatment response. World J Gastroenterol 2013; 19: 2691-2696 [PMID: 23674877 DOI: 10.3748/wjg.v19.i17.2691]

24 Chen SL, Morgan TR. The natural history of hepatitis C virus (HCV) infection. Int J Med Sci 2006; 3: 47-52 [PMID: 16614742]

25 Bonnard P, Elsharkawy A, Zalata K, Delarocque-Astagneau E, Biard L, Le Fouler L, Hassan AB, Abdel-Hamid M, El-Daly M, Gamal ME, El Kasas M, Bedossa P, Carrat F, Fontanet A, Esmat G. Comparison of liver biopsy and noninvasive techniques for liver fibrosis assessment in patients infected with HCV-genotype 4 in Egypt. J Viral Hepat 2015; 22: 245-253 [PMID: 25073725 DOI: 10.1111/jvh.12285]

26 Allam WR, Barakat A, Zakaria Z, Galal G, Abdel-Ghafar TS, El-Tabbakh M, Mikhail N, Wakid I, Abdelwahab SF. Schistosomiasis does not affect the outcome of HCV infection in genotype 4-infected patients. Am J Trop Med Hyg 2014; 90: 823-829 [PMID: 24615138 DOI: 10.4269/ajtmh.13-0703]
